As of December 2025, the Drug Enforcement Administration (DEA), in coordination with the Department of Health and Human Services (HHS), has once more extended the COVID-19-era telemedicine flexibilities for prescribing controlled substances. Originally set to expire at the end of 2025, these waivers—rooted in the Ryan Haight Online Pharmacy Consumer Protection Act of 2008—continue to allow providers to prescribe Schedule II-V controlled medications via audio-visual telehealth without an initial in-person examination.
This marks yet another chapter in what has become telehealth’s protracted “temporary” phase, now stretching nearly six years since the pandemic’s onset.
The Ryan Haight Act and the Pandemic Waiver
Enacted in 2008 to combat online pharmacies abusing controlled substances, the Ryan Haight Act mandates at least one in-person evaluation before prescribing such drugs via telemedicine, with narrow exceptions. During the COVID-19 public health emergency (declared in 2020), the DEA waived this requirement to ensure uninterrupted access to medications like ADHD stimulants, pain relievers, and crucially, buprenorphine for opioid use disorder treatment.
Post-emergency, these flexibilities have been extended multiple times: first through 2023-2024, then via a “Third Temporary Extension” to December 31, 2025. As that deadline approached, indications emerged of a potential fourth extension, with advocacy from senators and providers emphasizing risks to rural and underserved patients.
The Latest Developments in Late 2025
By mid-November 2025, the DEA signaled readiness for further extensions amid regulatory reviews and a government funding resolution. Senators like Mark Warner urged swift action to preserve access for mental health and substance use disorder care. While full details of any fourth extension remain pending as of December 16, 2025, the pattern suggests continued status quo to allow time for permanent rules.
Proposed permanent frameworks, including special registrations for telemedicine prescribers, have faced delays and revisions, with over 38,000 public comments influencing cautious progress.
Why the “Endless” Extensions?
Proponents argue extensions prevent care disruptions, particularly for behavioral health where telehealth has proven life-saving. Critics worry about diversion risks without in-person safeguards. The DEA balances these by granting time to craft rules that expand access while mitigating abuse—evident in separate provisions for buprenorphine initiation.
This limbo fosters innovation in virtual care but hinders long-term planning for providers and platforms.
The Road Ahead: Toward Permanence?
With extensions buying time into 2026 or beyond, the telehealth ecosystem evolves: AI integration, hybrid models, and broader reimbursement. Yet, stakeholders await final rules—potentially including limited prescriptions without in-person visits or heightened scrutiny for certain drugs.
Telehealth’s temporary era persists, but its permanence in healthcare seems assured. Will the next extension finally bridge to lasting policy—or extend the loop once more? Providers and patients alike watch closely as access hangs in regulatory balance.